An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I

Résumé fourni par la source

AIMS: Ulotaront is an investigational trace amine-associated receptor 1 (TAAR1) agonist demonstrated to slow gastric emptying in schizophrenia patients with metabolic syndrome (MetSyn) and prediabetes type 2. Here we evaluate the effects of ulotaront on glucose-insulin dynamics in schizophrenia patients with MetSyn and prediabetes. METHODS AND METHODS: NCT05463770 was a Phase 1b clinical trial, with an open-label, multi-dose design comparing ulotaront's metabolic effects to each participant's baseline of prior antipsychotic treatment. Oral glucose tolerance test (oGTT), a mixed meal tolerance test (MMTT) and a spirulina breath test (GEBT) were conducted at a baseline of prior antipsychotic medication and repeated after up to 3 weeks of twice-a-day dosing of ulotaront. RESULTS: In oGTT and MMTT, mean changes from baseline AUCs for glucose, c-peptide and insulin were -19.7 h×mg/dL, -269 h×pg/mL, -41.0 h×uIU/mL, and -10.8 h×mg/dL, -2860 h×pg/mL, -132 h×mg/dL, respectively. Insulin response during the MMTT reached nominal statistical significance (p = 0.021, effect size = -0.7). The mean change from baseline gastric emptying time was -0.60 min. CONCLUSIONS: Despite limited sample size, primary endpoints favoured ulotaront over prior antipsychotics with respect to a reduction trend in glucose, c-peptide and insulin. The insulin response after a solid meal was nominally significant, suggesting that semi-chronic twice-a-day dosing of ulotaront might improve insulin dynamics in schizophrenia patients at high diabetes risk.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.